DGCI finds no violation in Maiden Pharma case as claimed by WHO

New Delhi : Country’s drug controller General of India (DCGI) has written a strongly worded letter to Rogerio Gaspar, Director, Regulation and Prequalification, WHO informing that all control samples of the products have been found to be complying with specifications. Government’s Central Drug Laboratory (CDL) which conducted quality tests on the samples lifted from Maiden pharmaceuticals – the Sonepat-based company which has been in the dock for allegedly causing deaths of children in Gambia has found the products to be complying with specifications, putting the onus on World Health Organisation (WHO) for “prematurely” blaming an Indian company for the deaths without any “independent verification”.